Temozolomide (TMZ) is the most common chemotherapy used to treat GBM and is given to patients deemed (via pathological analysis) to possess a methylated O-6-methylguanine-DNA methyltransferase (MGMT) promoter tumor type. This evidence concerns the gene MGMT and glioblastoma.